Loading…
Allogene Therapeutics, Inc. is projected to rise to $2.56 by 2027, a +36% move from its current price of $1.88. ALLO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $1.81 | $1.88 | $1.95 | +0.04% |
| Aug 3 | $1.79 | $1.88 | $1.98 | +0.07% |
| Aug 4 | $1.77 | $1.88 | $2.01 | +0.11% |
| Aug 5 | $1.75 | $1.88 | $2.03 | +0.15% |
| Aug 6 | $1.74 | $1.88 | $2.04 | +0.19% |
| Aug 7 | $1.72 | $1.88 | $2.06 | +0.22% |
| Aug 8 | $1.71 | $1.88 | $2.08 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.71 | $1.88 | $2.08 | +0.26% |
| Week 2 | $1.65 | $1.89 | $2.17 | +0.52% |
| Week 3 | $1.60 | $1.89 | $2.24 | +0.79% |
| Week 4 | $1.57 | $1.90 | $2.31 | +1.05% |
| Week 5 | $1.53 | $1.90 | $2.37 | +1.31% |
| Week 6 | $1.51 | $1.91 | $2.42 | +1.58% |
| Week 7 | $1.48 | $1.91 | $2.47 | +1.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company that develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
The company is developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). It develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc).
The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics, Inc. (ALLO) is currently priced at $1.97 with a market cap of $679.95M. It is ranked 2621.
The forecast highlights a path of upside, with the average price rising from $1.97 in 2026 to $3.08 in 2030 and to $12.90 in 2050.
Max prices in the forecast reach $4.79 in 2030, $14.70 in 2040, and $26.83 in 2050, with sentiment turning bullish in most years and ROIs advancing to 56.6% by 2030 and higher later.
Note: forecasts are estimates and not guarantees of future results.
A major floor 27.7% below — a decisive break under it would weaken the trend.
The nearest floor, 11.7% below — buyers have tended to step in here.
The nearest ceiling, 18.1% above — a clean break opens room to run.
A major ceiling 62.8% above — clearing it would confirm fresh momentum.
Key ALLO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALLO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.81 | Buy | $1.85 | Buy |
| MA 10 | $1.81 | Buy | $1.84 | Buy |
| MA 20 | $1.89 | Sell | $1.88 | Buy |
| MA 50 | $1.97 | Sell | $1.97 | Sell |
| MA 100 | $2.16 | Sell | $2.00 | Sell |
| MA 200 | $1.86 | Buy | $1.93 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.69 | Neutral |
| Stoch RSI (14) | 76.71 | Neutral |
| CCI (20) | -6.80 | Neutral |
| Williams %R (14) | -29.03 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -1.05 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 70.97 | Neutral |
| TRIX (15) | -0.45 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 49.25 | Neutral |
| Momentum (10) | 0.09 | Buy |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 1.87 | Buy |
| ADX (14) | 16.24 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is bullish overall. RSI14 is 50, and the trend is supported by price action around key moving averages.
The SMA50 is $1.97 and the SMA200 is $1.86, with near-term support at $1.66 and resistance at $2.22. The 30-day price range runs from $1.55 to $2.51, signaling a relatively tight but constructive swing in prices.
Annualized volatility stands at 70, indicating a high level of price movement over a yearly horizon.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.35 | $1.88 | $2.68 | 0% | Neutral | |
| $1.98 | $2.56 | $3.54 | +36% | Bullish | |
| $1.99 | $2.68 | $3.89 | +43% | Bullish | |
| $1.86 | $2.58 | $3.89 | +37% | Bullish | |
| $1.91 | $2.74 | $4.25 | +46% | Bullish | |
| $1.87 | $2.75 | $4.39 | +46% | Bullish | |
| $2.09 | $3.15 | $5.14 | +68% | Bullish | |
| $2.56 | $3.95 | $6.59 | +110% | Bullish | |
| $2.55 | $4.03 | $6.85 | +114% | Bullish | |
| $2.75 | $4.44 | $7.70 | +136% | Bullish | |
| $3.43 | $6.13 | $11.45 | +226% | Bullish | |
| $4.56 | $9.77 | $20.34 | +420% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.35 | $1.88 | $2.33 | +0.00% |
| September 2026 | $1.66 | $1.98 | $2.45 | +5.38% |
| October 2026 | $1.61 | $1.94 | $2.44 | -1.83% |
| November 2026 | $1.60 | $1.95 | $2.47 | +0.28% |
| December 2026 | $1.71 | $2.09 | $2.68 | +7.32% |
Click any year to see its month-by-month ALLO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ALLO to range from $1.35 to $2.68 through 2026. The $1.88 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ALLO price prediction for 2027 points to an average of $2.56 (low $1.98, high $3.54) — a potential gain of +36% on today's $1.88. Momentum favours further upside here.
In 2028, ALLO is projected to trade between $1.99 and $3.89, averaging $2.68 — a potential gain of +43% from today's $1.88. That is up +5% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Allogene Therapeutics, Inc.'s 2029 outlook centres on $2.58, within a $1.86 to $3.89 range. That is -4% versus the projected 2028 average. That marks a +37% change versus current levels. Momentum favours further upside here.
By 2030, ALLO could reach as high as $4.25, with a base case around $2.74 and support toward $1.91 — roughly +46% from $1.88. Buyers look set to stay in control over this stretch.
Expect ALLO to range from $1.87 to $4.39 through 2031. The $2.75 average target implies a +46% move from current prices. That is up 0% on the projected 2030 average. Momentum favours further upside here.
The ALLO price prediction for 2032 points to an average of $3.15 (low $2.09, high $5.14) — a potential gain of +68% on today's $1.88. Buyers look set to stay in control over this stretch.
In 2033, ALLO is projected to trade between $2.56 and $6.59, averaging $3.95 — a potential gain of +110% from today's $1.88. That is up +25% on the projected 2032 average. Momentum favours further upside here.
Allogene Therapeutics, Inc.'s 2034 outlook centres on $4.03, within a $2.55 to $6.85 range. That is up +2% on the projected 2033 average. That marks a +114% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ALLO could reach as high as $7.70, with a base case around $4.44 and support toward $2.75 — roughly +136% from $1.88. Momentum favours further upside here.
Expect ALLO to range from $3.43 to $11.45 through 2040. The $6.13 average target implies a +226% move from current prices. That is up +38% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ALLO price prediction for 2050 points to an average of $9.77 (low $4.56, high $20.34) — a potential gain of +420% on today's $1.88. Momentum favours further upside here.
Investing $1,000 in ALLO today (≈ 531.914894 ALLO) could be worth
$5,196.44
+$4,196.44 (+420%) by 2050 · US Dollar
Based on the average projected ALLO price of $9.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALLOwould be worth at today's price.
$1,000 invested in ALLO on Jul 31, 2025 (≈ 813.008117 ALLO) would be worth
$1,528.46
+$528.46 (+52.8%) today · 1.53× · US Dollar
Based on a ALLO entry price of $1.23 vs. today's $1.88.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.74 | $1,080.46 | +8.0% |
| 1 month ago | $2.11 | $891 | -10.9% |
| 3 months ago | $2.15 | $874.42 | -12.6% |
| 6 months ago | $1.87 | $1,005.35 | +0.5% |
| 1 year ago | $1.23 | $1,528.46 | +52.8% |
| All time (5.0y) ago | $22.59 | $83.22 | -91.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALLO forecast.
Our base-case forecast reaches $3.80 around 2033.
Implied market cap at $3.80: $1.31B
The multi-year forecast shows a persistent uptrend in average prices and expanding ROIs, especially after 2026. In 2026, the avg is $1.97 with ROI 0 and sentiment NEUTRAL. By 2027, the avg rises to $2.73 with ROI 38.3% and sentiment BULLISH, followed by 2028 at $2.90 with ROI 47.1% and 2029 at $2.85 with ROI 44.8%.
In 2030, the avg is $3.08 with ROI 56.6% and sentiment BULLISH, and 2031 shows $3.19 with ROI 62.1% while remaining bullish. The path continues to 2032 with $3.80 (ROI 92.8%), 2033 with $4.77 (ROI 142.3%), 2034 with $4.86 (ROI 146.6%), and 2035 with $5.40 (ROI 173.9%), all labeled bullish.
Looking farther out, 2040 carries an avg of $7.87 (ROI 299.6%) and 2050 an avg of $12.90 (ROI 554.8%), with bullish sentiment across these years. These are estimates, not guarantees, and actual results may differ.
Tap a question to reveal the answer.
Avg price $3.08; min $2.16; max $4.79; ROI 56.6%; sentiment BULLISH.
Forecast shows bullish sentiment from 2027 onward, with 2027 avg $2.73 and ROI 38.3%, 2028 avg $2.90 and ROI 47.1%, 2029 avg $2.85 and ROI 44.8%, 2030 avg $3.08 and ROI 56.6%, continuing with higher ROIs through 2050 (e.g., ROI 62.1% in 2031 and 554.8% in 2050). The 2026 reading is NEUTRAL with ROI 0.
Yes—the forecast max price reaches $14.70 in 2040 and $26.83 in 2050, with 2035 max $9.34.
Current price $1.97; Market cap $679.95M; Rank 2621.
30-day range: low $1.55, high $2.51.
Allogene Therapeutics, Inc. Community Discussion
0Share your Allogene Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.